Can a serious game-based cognitive training attenuate cognitive decline related to Alzheimer's disease?
Information about the intervention that will be tested in the study
Tablet-based cognitive training game, targeting the cognitive domains mostly affected by Alzheimer’s disease, daily for 20 minutes.
Will all participants receive the same intervention?
Participants will be selected at random to either receive one of the following options:
- Computerised cognitive training for three months at home with weekly on-site group meetings, then six months at home with monthly on-site group meetings
- Watch documentaries for three months at home, then do computerised cognitive training for three months at home (active control group)
- Computerised cognitive training with a delay of three months (wait-list control group).
Information about participating in the study
What are the researchers trying to find out?
The purpose of the study is to evaluate if computerised-cognitive training is able to attenuate cognitive decline related to Alzheimer's disease.
How long will the study last?
What your involvement will entail?
- Participants will be asked to complete some tests to access memory, verbal fluency and visuospatial abilities
- Participants will be also requested to complete brain scan (MRI).
Further information on the procedures, tests and number of visits can be obtained from the study team.
Who can participate in this study?
Who can participate in the study?
To take part in the study, participants must:
- Be 60 to 85 years old
- Have a clinical diagnosis of Alzheimer's disease
- Be at increased risk for developing dementia.
Who cannot participate in the study?
People cannot take part in the study if they have:
- Contraindications for brain scans (MRI)
- Substance abuse
- Severe medical conditions.
The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study.
Information for your doctor
Study contact information
Esther Brill email@example.com
Christine Krebs firstname.lastname@example.org
Link to full text
The information contained in this document is based on information available on public registries (e.g. clinicaltrials.gov website) on January 2023.